Results 111 to 120 of about 486,983 (268)

Small molecule tyrosine kinase inhibitors in pancreatic cancer

open access: yesBiologics: Targets & Therapy, 2008
Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for ...
Sachin Gupta, Bassel F El-Rayes
doaj  

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

open access: yesEfficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook   +16 more
doaj   +1 more source

OA19.05 Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer [PDF]

open access: bronze, 2023
Seshiru Nakazawa   +30 more
openalex   +1 more source

Serotonergic System‐Targeted Nucleic Acid Hydrogel Coordinates Excitability Restoration and Circuit Reconstruction for Spinal Cord Injury Therapy

open access: yesAdvanced Materials, EarlyView.
The study reports a DNA/RNA heteroduplex hydrogel (SeroPTEN‐CG) that undergoes DNase‐mediated hydrogel‐to‐nanogel transition for spinal cord injury therapy by targeting the serotonergic system, combining 5‐hydroxytryptamine (5‐HT)‐mediated excitability restoration to reactivate dormant interneurons with phosphatase and tensin homolog (PTEN)‐targeted ...
Chunlin Li   +19 more
wiley   +1 more source

Mice Devoid of Fer Protein-Tyrosine Kinase Activity Are Viable and Fertile but Display Reduced Cortactin Phosphorylation

open access: green, 2001
Andrew W. Craig   +4 more
openalex   +1 more source

CHRONIC MYELOID LEUKEMIA STUDY FOR RESPONSE PATTERN WITH TYROSINE KINASE INHIBITORS

open access: hybrid, 2023
Namita Padwal   +4 more
openalex   +1 more source

Cholesterol‐DNA Origami Nanostructures for Synthetic Lipid Rafts Induce Early T Cell Activation Signals

open access: yesAdvanced Materials Interfaces, EarlyView.
Here, we present a nanotechnology approach to construct synthetic lipid rafts on the live T cell membrane, leveraging a versatile DNA origami‐enabled platform named as the “cholesterol nano‐patch” (CNP). Our investigation highlights the effectiveness of DNA nanotechnology in exploring the impact of nanoscale arrangement of cholesterols on the ...
Yunmin Jung   +4 more
wiley   +1 more source

End‐to‐End Sensing Systems for Breast Cancer: From Wearables for Early Detection to Lab‐Based Diagnosis Chips

open access: yesAdvanced Materials Technologies, EarlyView.
This review explores advances in wearable and lab‐on‐chip technologies for breast cancer detection. Covering tactile, thermal, ultrasound, microwave, electrical impedance tomography, electrochemical, microelectromechanical, and optical systems, it highlights innovations in flexible electronics, nanomaterials, and machine learning.
Neshika Wijewardhane   +4 more
wiley   +1 more source

Smart REASSURED Sensors via Machine‐Augmented Printable On‐Paper Arrays

open access: yesAdvanced Sensor Research, EarlyView.
This perspective highlights the emerging role of pattern‐recognition, printable on‐paper sensor arrays for intelligent PoC diagnostics. It discusses how paper's inherent limitations can be overcome through surface modification and scalable printing, and how machine‐learning analysis of cross‐reactive arrays enables multiplexed, low‐cost, and REASSURED ...
Naimeh Naseri, Saba Ranjbar
wiley   +1 more source

A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation

open access: green, 2019
Francisco Lopez‐Tapia   +5 more
openalex   +1 more source

Home - About - Disclaimer - Privacy